by Stacey Johnson | May 16, 2014
. Last November, I wrote about CCRM’s new Regenerative Medicine Video Network and featured an original video with Dr. Stephen Minger, Chief Scientist, Cellular Sciences GE Healthcare Life Sciences in the UK. If you enjoyed his industry perspective and insights on...
by Mark Curtis | May 14, 2014
. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more....
by Mark Curtis | Apr 30, 2014
. Of all the formidable challenges that a biotechnology company will stumble upon in its quest to commercialize, perhaps there is none more frustrating than a failure to get a product reimbursed by payers. After years of navigating the gauntlet of risk that is...
by Roshan Yoganathan | Apr 17, 2014
Recently Revmedx, a pioneer in the biomaterial wound dressing field, made some waves with the commercialization of its product XStatTM . XStatTM received a lot of press because of its FDA approval for use against gunshot wounds and shrapnel-related injuries in the...
by Mark Curtis | Mar 11, 2014
. Welcome to your update from the clinic for the month of February! OncoMed is the leader in news this month with various Phase 1b trials for its cancer stem cell-targeting fusion protein. Immunocellular Therapeutics and StemCells Inc. file orphan drug designations...
by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
Comments